Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis, Thai Government Agree To Free Gleevec, No Push For Compulsory License

This article was originally published in PharmAsia News

Executive Summary

Novartis and its regional headquarters in Thailand agreed to provide its Gleevec (imatinib mesylate) free to poorer cancer patients in the country in exchange for the government dropping its compulsory licensing threat. The outgoing public health minister who brokered the deal said he would like other drug makers to take similar steps or face compulsory licensing. The deal means Novartis is to offer free access to leukemia and gastrointestinal cancer patients under the universal health care plan and continue marketing the drug to Thais who can afford the market price. In Thailand, the market price is 20 times higher than a generic produced in India. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts